I. Coppens et al., Production of Neisseria meningitidis transferrin-binding protein B by recombinant Bordetella pertussis, INFEC IMMUN, 69(9), 2001, pp. 5440-5446
Neisseria meningitidis serogroup B infections are among the major causes of
fulminant septicemia and meningitis, especially severe in young children,
and no broad vaccine is available yet. Because of poor immunogenicity of th
e serogroup B capsule, many efforts are now devoted to the identification o
f protective protein antigens. Among those are PorA and, more recently, tra
nsferrin-binding protein B (TbpB). In this study, TbpB of N. meningitidis w
as genetically fused to the N-terminal domain of the Bordetella pertussis f
ilamentous hemagglutinin (FHA), and the fha-tbpB hybrid gene was expressed
in A pertussis either as a plasmid-borne gene or as a single copy inserted
into the chromosome. The hybrid protein was efficiently secreted by the rec
ombinant strains, despite its large size, and was recognized by both anti-F
HA and anti-TbpB antibodies. A single intranasal administration of recombin
ant virulent or pertussis-toxin-deficient, attenuated B. pertussis to mice
resulted in the production of antigen-specific systemic immunoglobulin G (I
gG), as well as local IgG and IgA. The anti-TbpB serum antibodies were of t
he IgG1, IgG2a, and IgG2b isotypes and were found to express complement-med
iated bactericidal activity against N. meningitidis. These observations ind
icate that recombinant B. pertussis may be a promising vector for the devel
opment of a mucosal vaccine against serogroup B meningococci.